CAS: 67634-20-2
Glisindamide (CAS: 67634-20-2) is an oral antidiabetic drug belonging to the first-generation sulfonylurea class. It functions by stimulating the beta cells of the pancreas to release more insulin, thereby lowering blood glucose levels. It was developed for the management of type 2 diabetes mellitus.
Primarily used for the treatment of non-insulin-dependent (type 2) diabetes mellitus in adults to help control hyperglycemia when diet and exercise alone are insufficient.
Its primary application is pharmaceutical, serving as a medication prescribed for the chronic management of blood sugar levels in patients with type 2 diabetes. It is administered orally.
A major concern with Glisindamide, like other sulfonylureas, is the risk of hypoglycemia (low blood sugar), which can be severe. Other potential side effects include gastrointestinal disturbances (e.g., nausea, vomiting, diarrhea), skin reactions (e.g., rash, itching), and weight gain. It is contraindicated in type 1 diabetes, diabetic ketoacidosis, severe renal or hepatic impairment, pregnancy, and lactation. Careful monitoring of blood glucose and awareness of potential drug interactions are essential.
Glisindamide; N-[2-[[[1-(4-chlorophenyl)-3-methyl-4-oxo-2-pyrazolin-5-yl]sulfonyl]amino]ethyl]acetamide; Zambon 500; Z 500.
Search suppliers instantly using CAS or chemical name
Search Suppliers →